Multimodal treatment of pediatric patients with Askin’s tumors: our experience

Table 1 Patients’ characteristics, treatments, and follow-up

Patient gender	Age at diagnosis (years)	Tumor size (cm)	Tumor volume (cm³)	LDH (UI/L)	Metastasis	Neoadjuvant/adjuvant CT	RT	Relapse (months after remission)	Survival	Follow-up (months since diagnosis)
1 M	12	11	29.7	475	Yes	6 VIDE + 2 VAI, BUS/MELPH	No	No	Yes	125
2 M	6	6	62.4	460	No	6 VIDE + 8 VAI	Yes	No	No	11.4
3 F	13	7	211.1	461	No	6 VIDE + 8 VAI	Yes	No	Yes	170.9
4 M	14	15	1404	560	No	6 VIDE+ 8 VAI	Yes	No	Yes	76.5
5 M	9	9	345.8	510	No	6 VIDE + 8 VAI	No	Yes	No	35.6
6 F	15	4.5	166.4	210	No	6 VIDE + 8 VAI	Yes	No	Yes	104.2
7 F	10	16	457.6	320	No	6 VIDE + 8 VAI	Yes	No	No	29
8 M	11	7	117.9	280	No	6 VIDE + 8 VAI	No	No	Yes	28.7
9 F	6	5.5	50.5	420	Yes	6 VIDE + 2 VAI, BUS/MELPH	No	No	Yes	53.1

M male; F female; VIDE vincristine, ifosfamide, doxorubicine, D-actinomycin; VAI vincristine, D-actinomycin, ifosfamide; BUS/MELPH busulfan/melphalan; RT radiotherapy

ISSN: 1477-7819